Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announce...
Trials-in-progress poster of ongoing pivotal Phase 3 trial of DNA-mediated immunotherapy accepted at both IGCS and ESMO Congres...
IMNN-001 program is currently advancing its OVATION 3 pivotal Phase 3 trial per planLAWRENCEVILLE, N.J., Oct. 23, 2025 (GLOBE N...
Investor event to provide update on pivotal Phase 3 study of IMNN-001 to be held in New York City on November 10, 2025Program w...
LAWRENCEVILLE, N.J., Oct. 17, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company focused on developi...
Prestigious European Society for Medical Oncology Conference "trials-in-progress" sessionPivotal OVATION 3 trial of its...
OVATION 3 pivotal Phase 3 trial is currently advancing IMNN-001, with several patients being treatedLAWRENCEVILLE, N.J., Sept. ...
